Updated Jul 16, 2026
Cavalier Jason is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $9K.
Jason Cavalier is the Chief Financial Officer of Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on developing drug and delivery solutions for ENT diseases. He has been involved in the company's financial operations and reporting.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-04-03 | LYRA | Lyra Therapeutics, Inc. | D — Derivative transaction | 667 | $0.00 | |
| 2026-01-08 | LYRA | Lyra Therapeutics, Inc. | S — Open-market sale [10b5-1] | 769 | $3.36 | $3K |
| 2025-07-10 | LYRA | Lyra Therapeutics, Inc. | S — Open-market sale | 684 | $8.91 | $6K |
| 2024-10-18 | LYRA | Lyra Therapeutics, Inc. | A — Grant or award | 100.0K | $0.00 |
Jason Cavalier is the Chief Financial Officer of Lyra Therapeutics, Inc., a clinical-stage therapeutics company focused on developing drug and delivery solutions for ENT diseases. He has been involved in the company's financial operations and reporting.…
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($9K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Cavalier Jason profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.